BIOTECH FRANCE
MEMORIES

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Search Companies Events Environment Memories Home-Biotech

AbAg | Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Alphelys | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Atlantic Bone Screen | Aureus Pharma | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Cellectis | Cellial Technologies | CellVax | CellVir | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | DBV Technologies | Diatos | DNA Therapeutics | Domain Therapeutics | Dynabio | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | Fovea Pharmaceuticals | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | GTP Technology | Helios Biosciences | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | Innate Pharma | InnaVirVax | IntegraGen | Ipsogen | I-Stem | Ivagen | Karcinolys | Keosys | LibraGen | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Meristem Therapeutics | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | Nautilus Biotech | Neorphys | Neovacs | Netris-Pharma | Neuronax | NicOx | Nokad | Nova Decision | Novagali | Novexel | NovoCIB | Novotec | ObeTherapy | Oligovax | Oncodesign | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | PraXcell | Proteogenix | Protéus | Protexel | PX’Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | ShigaMediX | Sisène Biotechnologies | Skuld-Tech | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theraptosis | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | Vaxon Biotech | Vectalys | VigiCell | Vivalis | XenTech |

  • Hereafter is a partial list of significant Biotech companies today disappeared or not any more legally French, to witness the memory of those entrepreneurs who took the risks for a risky venture : some were acquired (and a subsidiary may still be active in France), some were merged (and their name absorbed), some were liquidated... but most entrepreneurs started again
  • In a Biotech world that moves swiftly memory soon holds many holes... any data additions-contributions will be highly appreciated using the CONTACTEXPRESS form
  • Beware, obviously, website URL and e-mails may well be outdated
  • Pharmaclient : Mission, Keywords Biotech, Services... MORE?
  • Voici une liste partielle des entreprises Biotechs importantes, aujourd'hui disparues ou bien plus du tout Françaises (légalement), éditée pour rendre hommage aux entrepreneurs qui ont pris des risques pour un projet à risques : certaines ont été acquises (et une filiale peut encore être active en France), certaines ont été fusionnées (et leur nom a été absorbé), certaines ont été liquidées... mais la plupart des entrepreneurs ont recommencé
  • Dans un monde des Biotechs qui bouge très vite, la mémoire tôt se remplit de nombreux trous... toutes additions-contributions pour les données, en utilisant le formulaire de CONTACTEXPRESS seront vivement appréciées
  • Attention, évidemment, les URL et courriels sont probablement obsolètes
  • Pharmaclient : Mission, Mots-clés Biotech, Services... PLUS?

 

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

 

 

 

* ADIATEC *

1998 - Bretagne
Nantes
www.adiatec.fr

Design, Diagnostics
Key words: Immunoassay kits, Ophthalmology, Allergy, Eutest, Lacrytest, Mabtest, Amplitest
Mission: to develop and manufacture rapid assays for in vivo/in vitro diagnostics of ocular allergy, babies and children allergy, and for murine monoclonal antibodies isotyping
Clients: analysis labs, research labs
info@adiatec.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Lesser (Joël) [founder]
Sc.Dir.:
Fin.Dir.:
BusDev: Brèche (Sébastien)
Financers (Hist.): privately owned, business angels

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Ophthalmo
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2005 .12 Company liquidation INFO [7 years]
1998 .01 Company founded by Joël Lesser ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* APTANOMICS *

2001 - Rhône-Alpes
Lyon
www.aptanomics.com

Discovery, Drugs
Key words: Aptameres, Peptides, Cancer, Aptascreen, Aptaprint
Mission: to develop new treatments based on discovery of targets involved in signalling pathways that are deregulated in a broad range of cancers
Clients: Pharmaceutical industry (own development up to preclinical stage)
info@aptanomics.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.: Chatelier (Jean)
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.): AGF P.E., CDC Ixis, Ventech, Biogestion

Turnover (M€) : 0.05 (2006)
Total funding (M€) : 7.0
Last funding (M€) : 7.0
Focus : Cancers
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2007 .07 Financial complete burn-out and bankruptcy INFO [6 years]
2006 .11 Divestiture of some R&D assets to Imaxio (UK) LICOUT [5 years]
2005 .06 Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation R&D [4 years]
2003 .05 Nomination : Michael Courtney [ex-Transgene], as CEO ORGN [2 years]
2002 .11 1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech RFINA [1 year]
2001 .03 Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* BIONEXIS PHARMACEUTICALS *

2002 - IDF
Paris
www.bionexis.com

Discovery, Drugs
Key words: Imaging radio-pharmaceuticals, Targeted drugs, Lipid-protein interaction, Apoptosis, Afim
Mission: to develop intelligent molecules for imaging and therapeutic applications, based on know-how on membrane protein-lipid interactions, focused on pathological apoptosis
Clients: Prescribers
info@bionexis.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Rodgers (Brid) [Ph.D. molecular biology, MBA, ex-Monitor]
Sc.Dir.: Russo-Marie (Françoise) [co-founder, ex-Inserm] & Samson (Alain) [co-founder, University professor]
Fin.Dir.:
BusDev:
Financers (Hist.): Edmond de Rotschild I.P., Bioam, Sophia Euro lab, FCJE (CDC), CEA

Turnover (M€) :
Total funding (M€) : 6.0
Last funding (M€) : 6.0
Focus : Cancers
Position : Incubator
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2004 .12 Company liquidation INFO [2 years]
2004 .02 1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA RFINA [2 years]
2004 .02 Company move from Saclay (CEA) to Paris (Biotech) RELOC [2 years]
2002 .02 Company founded by Françoise Russo-Marie and Alain Samson ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* BIONISIS *

1999 - IDF
Le Plessis (near Paris)
www.bionisis.com

Contract, Research
Key words: High-throughput, Purification, OPLC technology (Optimum Performance Laminar Chromatography), Sorbent beds
Mission: to provide third parties with proprietary solutions for the separation, purification and analysis of chemical and biochemical mixtures resulting from organic synthesis, natural product extraction and biological fluids
Clients: Pharmaceutical industry, Research labs
webmaster@bionisis.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Manach (Michel)
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.): Sofimac, Ventech, Siparex, OTC A.M.

Turnover (M€) : 0.5 (2004)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Subcontractor
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .03 Company liquidation INFO [9 years]
2002 .09 2nd round-financing : 2.5 M€ RFINB [3 years]
1999 .10 Company founded by unknown entrepreneurs ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* CAREX *

2001 - Alsace
Strasbourg
www.carex.fr

Discovery, Drugs
Key words: Diabetes
Mission: to undertake innovative research of metabolic diseases, such as type 2 diabetes, obesity and dyslipidemia
Clients: Pharmaceutical industry
carex@carex.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Race (Geoffrey) [ex-Adprotech]
Sc.Dir.:
Fin.Dir.: Margetson (Shelley)
BusDev:
Financers (Hist.): Sofinnova Partners, GIMV, Mara Ventures (USA), Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM

Turnover (M€) :
Total funding (M€) : 31.0
Last funding (M€) : 25.0
Focus : Metabolism
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .05 Acquisition by 7TM Pharma (Denmark) ACQ- [5 years]
2004 .03 2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders RFINB [3 years]
2002 .07 Nomination : Geoffrey Race, as CEO [1 year]
2002 .04 1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures RFINA [1 year]
2001 .11 Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* CELOGOS *

2001 - IDF
Paris
www.celogos.fr

Discovery, Drugs
Key words: Muscle regeneration, Cell repair, Technology platform, Rational Cell Design (RCD), Stress urinary incontinence, Anal incontinence, Ocular myopathies
Mission: to develop and produce innovative cell-based technologies in the field of cellular medicine
Clients: Pharmaceutical industry
contact@celogos.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Ulmann (André) [M.D., Ph.D. endocrinology, ex-Hoechst, Roussel Uclaf]
Sc.Dir.: Pinset (Christian) [founder, M.D., ex-CNRS, Institut Pasteur]
Fin.Dir.:
BusDev:
Financers (Hist.): privately owned

Turnover (M€) :
Total funding (M€) : 3.0
Last funding (M€) : n.a.
Focus : Muscle
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .01 Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO ACQ- [5 years]
2005 .11 Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds R&D [4 years]
2001 .08 Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* CELLPEP *

1998 - IDF
Paris
www.cellpep.fr

Delivery, Drugs
Key words: Generics, Value-added, Long acting release, Formulation, Octreotide, Goserelin
Mission: to develop therapeutics in oncology and infectious diseases
Clients: Pharmaceutical industry
jpboulan@cellpep.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: de Rougé (Bonabes) [co-founder, M.D., ex-Servier, Beaufour-Ipsen]
Sc.Dir.: Mollard (Michel) [co-founder, also Seventure, ex-Beaufour-Ipsen, Cooper]
Fin.Dir.:
BusDev:
Financers (Hist.): Seventure

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .03 Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com) ACQ- [8 years]
2003 .03 Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes RFIN [5 years]
1998 .00 Company founded by Bonabes de Rougé, Michel Mollard and others ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* DRUGABUSE SCIENCES *

1994 - Rhône-Alpes
Villeurbanne
(near Lyon)
www.drugabusesciences.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: Antagonism, Addiction, Alcoholism, Toxicomany, Cocaine, Opioids, Naltrexone Depot
Mission: to discover, develop and market medications for the treatment of alcohol and substance abuse and dependence
Clients: Prescribers
mdupire@drugabusesciences.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Langlois (Patrick) [born 1945, ex-Aventis (Board member, Rhône Poulenc]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.): CDC Ixis, Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Addiction
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .05 Company liquidation : legal dissolution INFO [14 years]
2007 .01 Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms ACQ- [13 years]
2006 .06 Listing on Alternext processed : 20 M€ expected (failed) PBO [12 years]
2004 .01 Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis ACQ+ [10 years]
2001 .04 Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management RFIN [7 years]
1999 .10 Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M. RFIN [5 years]
1994 .12 Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* ENDOCELLS *

2004 - IDF
Paris
www.no-website.net

Design, Therapy
Key words: Cell therapy, Transplantation, Type 1 Diabetis, Insulin
Mission: to generating lines of human pancreatic beta cells immortalized in culture for transplantation therapies
Clients: Research labs
dslagel@esperanteventures.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Slagel (Dean) [born 1970]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Diabetes
Position : Incub
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .05 Acquisition by Esperante Ventures (Holland) ACQ- [4 years]
2004 .08 Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm] ORGF [0 year]

Actualisation / Updating: 24-Sep-2008

* GÉNOPOÏETIC *

1993 - Rhône-Alpes
Miribel (Ain)
www.genopoietic.fr

Discovery, Drugs
Key words: Autologous vaccine
Mission: to develop autologous chondrocytes for cartilage repair, gene therapy to treat cancer, as well as to treat graft-versus-host disease (innovative anticancer drugs)
Clients: Pharmaceutical industry
info@genopoietic.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Star-up |
Managing Dir.: Fourthin (Isabelle) [M.D., MBA Essec, ex-MSD, Osteotech]
Sc.Dir.: Fourthin (Isabelle)
Fin.Dir.:
BusDev:
Financers (Hist.): Rhône-Poulenc Rorer (Gencells), then Avax (listed on US Stock Exchange)

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .11 Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director ORGN [15 years]
2000 .08 Acquisition by Avax Technologies, Philadelphia (USA) ACQ- [7 years]
1994 .11 Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials RFIN [1 year]
1993 .12 Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* GENSET *

1989 - IDF
Paris
www.genset.fr

Discovery, Drugs
Key words: Pharmacogenomics, DNA sequences
Mission: to undertake research programs in the field of genomics, to analyze the regulatory sequences of the human genome and to initiate the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases, notably for CNS and metabolism
Clients: Pharmaceutical industry, Research labs
contacts@genset.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Pernet (André)
Sc.Dir.: Vassuer (Marc) [co-founder, Ph.D.]
Pharm.Dir.: Ravel (Denis) [Ph.D.]
Fin.Dir.:
BusDev:
Financers (Hist.): J.P. Morgan, Public

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Incub
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2002 .06 Acquisition by Serono (Switzerland) ACQ- [13 years]
1996 .06 Listing on Nasdaq : 100 MUS$ (about 80 M€) PBO [7 years]
1989 .00 Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* HEMOSYSTEM *

1999 - Méditerranée
Marseille
www.hemosystem.com

Discovery, Diagnostics
Key words: Bacteria, Micro-array, ScanSystem
Mission: to develop new diagnostic tools and associated devices to improve safety in blodd transfusion medecine
Clients: Blood transfusion centers, Hospitals
info@hemosystem.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Hermet (Jean-Pierre) [founder, MBA, ex-Bentley Pharma, American Home Products, Allergan]
Sc.Dir.: Besson-Faure (Isabelle) [Pharm.D., ex-Stago]
Fin.Dir.: Allione (Monique) [Sup de Co (Marseille), DESCF, ex-Quater Oats, Irex (Synthelabo)]
BusDev:
Financers (Hist.): Société Générale A. M., XAnge, Avenir Finance Gestion, FJCE (CDC)

Turnover (M€) : 0.7 (2004)
Total funding (M€) : 5.3
Last funding (M€) : 3.0
Focus : Hematology
Position : Trade
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .10 Company liquidation INFO [7 years]
2004 .09 Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders RFIN [5 years]
1999 .05 Company founded by Jean-Pierre Hermet (CEO) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* IDM PHARMA *

1987 - IDF
Paris
www.idm-biotech.com

Discovery, Drugs
Key words: Melanoma, Sarcoma, Infectious diseases, Junovan
Mission: to develop innovative products that activate the immune system to treat cancers
Clients: Prescribers
idm@idm-biotech.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Romet-Lemonne (Jean-Loup) [co-founder]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .02 Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan R&D [21 years]
2007 .06 Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne ORGN [20 years]
2005 .03 Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma ACQ- [18 years]
2002 .12 Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%) RFIN [15 years]
2002 .01 Partnering research agreement with Sanofi-Synthelabo R&D [15 years]
2000 .11 Round-financing: 48.9 M€ RFIN [13 years]
1993 .12 Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM) ORGF [6 years]

Actualisation / Updating: 12-Mai-2008

* NEURO3D *

2000 - Alsace
Mulhouse
www.neuro3d.com

Discovery, Drugs
(also, Contract, Research)
Key words: CNS, Psychiatry, Schizophrenia, Ocaperidone
Mission: to develop innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety
Clients: Prescribers
contact@neuro3d.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Woler (Charles)
Sc.Dir.:
Fin.Dir.: Coste (Julien)
BusDev:
Financers (Hist.): Sofinnova Partners, Apax Partners

Turnover (M€) : 1.0 (2004)
Total funding (M€) : 70.0
Last funding (M€) : 31.5
Focus : Multiple
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2007 .03 Liquidation and divestiture of R&D assets to Evotec (Germany) INFO [7 years]
2005 .05 Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning) CLIN [5 years]
2004 .12 4th round-financing : 31.5 M€, by previous shareholders RFIND [4 years]
2003 .09 3rd round-financing : 10.0 M€, by previous shareholders RFINC [3 years]
2003 .05 Acquisition of Neurofit (France), a biotech CRO ACQ+ [3 years]
2002 .09 2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders RFINB [2 years]
2002 .03 Licensing-out of Ocaperidone to Janssen (J&J) LICOUT [2 years]
2000 .11 1st round-financing : 7.6 M€, by founder V.C., Apax Partners RFINA [0 year]
2000 .09 Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* NEUROTECH *

1998 -
www.neurotech.fr

Discovery, Drugs
Key words: Retinatis, CNTF, Encapsulated Cell Technology
Mission: to develop sight-saving therapeutics for chronic retinal diseases
Clients: Prescribers
t.shepherd@neurotech.fr

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Shepherd (Tom)
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Ophthalmo
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .06 Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com ORGL [8 years]
2003 .11 4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity) RFIND [5 years]
2002 .01 Licensing-in agreement of CNTF with Amgen in all ophthalmology indications LICIN [4 years]
2001 .05 3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH) RFINC [3 years]
2000 .00 Set-up of US subsidiary in Lincoln ORGC [2 years]
1998 .10 Company founded by unknown entrepreneurs ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* OPI *

1999 - Rhône-Alpes
Lyon
www.orphan-opi.com

Discovery, Drugs
Key words: Orphan diseases, Hematology, Cancer, Transplants, Kidrolase, Erwinase
Mission: to discover and develop new treatment for orphan diseases
Clients: Pharmaceutical industry
opi@orphan-opi.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Alberici (Gilles) [founder, Pharm.D., Ph.D. immunotoxicology, ex-Mérieux, IMTIX-Sangstat]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.): founder, Biomérieux, Sofimac, CDC-PME, Innoveris, SPEF, Siparex

Turnover (M€) :
Total funding (M€) : 13.0
Last funding (M€) : 6.4
Focus : Multiple
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2007 .03 Acquisition by Eusa Pharma (USA) ACQ- [8 years]
2004 .04 3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders RFINC [5 years]
2003 .05 Acquisition of Diaclone (France) ACQ+ [4 years]
2003 .00 2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris RFINB [4 years]
2001 .00 1st round-financing : 1.1 M€, by previous shareholders RFINA [2 years]
1999 .00 Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International' ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* SYNT:EM *

1995 - Méditerranée
Nîmes
www.syntem.com

Discovery, Drugs
(also, Delivery, Drugs)
Key words: CNS, Brain barrier
Mission: to develop new drugs as well as to deliver compounds to the brain or other intracellular targets, based on proprietary Pep:trans and Acti:map technology platforms, in the field of CNS diseases
Clients: Prescribers
syntem@syntem.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Kaczorek (Michel)
Sc.Dir.:
Fin.Dir.: Waldron (Gordon)
BusDev:
Financers (Hist.): Apax Partners, Banexi Ventures, 3i, BankInvest, Lombart-Odier

Turnover (M€) :
Total funding (M€) : 32.0
Last funding (M€) : n.a.
Focus : CNS
Position : Clinical
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2006 .01 Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares ACQ- [11 years]
2004 .11 Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares ACQ- [9 years]
1995 .00 Company founded by Michel Kaczorek (CEO), Caroline Roussel ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* TRANSAT *

2002 - Rhône-Alpes
Saint-Priest
(near Lyon)
www.biotransat.com

Design, Drugs
(also Contract, Research)
Key words: Target delivery, Viral vectors, Functional genomics, Plasmid developments, Cellular models, Molecule libraries, RNA interference
Mission: to provide taylored cellular models and gene expression studies in functional genomics for third parties
Clients: Pharmaceutical industry, Biotech, Academic labs
transat@transatbiotechnology.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.: Chappuis (Sophie) [Ph.D., EM Lyon, ex-CNRS]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.): Evolem, Oseo, Région Rhône-Alpes, privately owned

Turnover (M€) : 0.5 (2006)
Total funding (M€) : 1.2
Last funding (M€) : 1.2
Focus : Genome
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2008 .03 Company liquidation INFO [6 years]
2006 .01 Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel SFIN [4 years]
2002 .12 Company founded by Sophie Chappuis and Marc Billaud (CNRS) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

* VALIGEN *

1996 - IDF
Courbevoie (near Paris)
www.valigen.com

Discovery, Drugs
Key words: Genomics, Chimeraplasty
Mission: to research in therapeutic target identification and validation using the tools of functional genomics and gene expression analysis, for treatments of cardio-vascular and metabolic conditions, and some cancers
Clients: Pharmaceutical industry, Agro industry
webmaster@valigen.com

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.: Tharaud (Cécile) [Polytechnique, Ph.D., MBA, ex-Glaxo, SB]
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers (Hist.):

Turnover (M€) : 0.18 (2001)
Total funding (M€) : 30.0
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : n.a.

History
DATEMILESTONETYPETIME
2002 .05 Company liquidation INFO [6 years]
2001 .05 Nomination : Cécile Tharaud, as CEO ORGN [5 years]
2000 .02 Acquisition of Kimeragen (USA), by merger ACQ+ [4 years]
1997 .02 Acquisition of Infogen (Germany) ACQ+ [1 year]
1996 .12 Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA) ORGF [0 year]

Actualisation / Updating: 12-Mai-2008

Actualisation / Updating: Jan 07 2009

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT
Pour retourner à la page d'accueil Biotech: BIENVENUE !

Haut de page :

Copyright J.H. Huber, Pharmaclient 2001-2009.

Pharmaclient, le site de la valorisation client en Pharma, est la vitrine des activités de conseil de Jean Huber: Stratégie, Communication, Relation Client en Pharma.